Circadian Rhythm of Irinotecan Tolerability in Mice

References

• Araki E., Ishikawa M., Iigo M., Koide T., Itabashi M., Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 1993; 84: 697–702
   PubMedGoogle Scholar
• Bjarnason G. A., Jordan R. Rhythms in human gastrointestinal mucosa and skin. Chronobiol. Int. 2002; 19(1)129–140, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bjarnason G. A., Jordan R. C. K., Sothern R. B. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am. J. Pathol. 1999; 154(2)613–622
   PubMed Web of Science ®Google Scholar
• Boughattas N., Lévi F., Fournier C., Lemaigre G., Roulon A., Hecquet B., Mathé G., Reinberg A. Circadian rhythm in toxicities and tissue uptake of 1,2-diaminocyclohexane (trans-1) oxalatoplatinum(II) in mice. Cancer Res. 1989; 49: 3362–3368
   PubMed Web of Science ®Google Scholar
• Caussanel J. P., Lévi F., Brienza S., Misset J. L., Itzhaki M., Adam R., Milano G., Hecquet B., Mathé G. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst. 1990; 82: 1046–1050
   PubMed Web of Science ®Google Scholar
• Dean P., Jett J. Mathematical analysis of DNA distributions derived from flow micro-fluorimetry. J. Cell Biol. 1974; 60: 523–527, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Douillart J. Y., Cunningham D., Roth A. D., Navarro M., James R. D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 2000; 355: 1041–1047, [CROSSREF]
   PubMedGoogle Scholar
• Dunlap J. C. Molecular bases for circadian clocks. Cell 1999; 96: 271–290, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fukuoka M., Niitani H., Suzuki A., Motomiya M., Hasegawa K., Nishiwaki Y., Kuriyama T., Ariyoshi Y., Negoro S., Masuda N., Nakajima S., Taguchi T. A phase I study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 1992; 10: 16–20
   PubMed Web of Science ®Google Scholar
• Gandia D., Abigerges D., Armand J. P., Chabot G., Da Costa L., De Forni M., Mathieu-Boue A., Herait P. CPT-11 induced cholinergic effects in cancer patients. J. Clin. Oncol. 1993; 11: 196–197
   PubMed Web of Science ®Google Scholar
• Giacchetti S. Chronotherapy of colorectal cancer. Chronobiol. Int. 2002; 19(1)207–219, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Giacchetti S., Zidani R., Goldwasser F., Brézault-Bonnet C., Tigaud J. M., Mormont C., Montembault S., Misset J. L., Lévi F. Chronomodulated CPT-11. A pilot study. Proc. Am. Soc. Clin. Oncol. 1999; 18: 259a, (abstr. 996)
   Google Scholar
• Goldwasser F., Shimizu T., Jackman J., Hoki Y., O’Connor P. M., Kohn K. W., Pommier Y. Correlation between S- and G2-phase arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 1996; 56: 4430–4437
   PubMed Web of Science ®Google Scholar
• Hsiang Y. H., Liu L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48: 1722–1726
   PubMed Web of Science ®Google Scholar
• Hsiang Y. H., Lihou M. G., Liu L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989; 49: 5077–5082
   PubMed Web of Science ®Google Scholar
• Hsiang Y. H., Hertzberg R., Hecht S., Liu L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985; 260: 14873–14878
   PubMed Web of Science ®Google Scholar
• Ikuno N., Soda H., Watanabe M., Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J. Natl. Cancer Inst. 1995; 87: 1876–1883
   PubMedGoogle Scholar
• Kawato Y., Aonuma M., Hirota Y., Kuga H., Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11 in the antitumor effect of CPT-11. Cancer Res. 1991; 51: 4187–4191
   PubMed Web of Science ®Google Scholar
• Kirichenko A. V., Rich T. A. Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration. Int. J. Radiat. Oncol. Biol. Phys. 1999; 44: 659–664, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Klein D. C., Moore R. Y., Reppert S. M. Suprachiasmatic Nucleus, the Mind's Clock. Oxford University Press, Oxford 1991; 467 pp
   Google Scholar
• Kume K., Zylka M. J., Sriram S., Shearman L. P., Weaver D. R., Jin X., Maywood E. S., Hastings M. H., Reppert S. M. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 1999; 98: 193–205, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lévi F. Chronotherapy of cancer. Lancet Oncology 2001; 2: 307–315, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lévi F. From circadian rhythms to cancer chronotherapeutics. Chronobiol. Int. 2002; 19(1)1–19, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lévi F., Zidani R., Misset J. L. For the International Organization for Cancer Chronotherapy Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681–686, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lévi F., Metzger G., Massari C., Milano G. Oxaliplatin. pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 2000b; 36: 1–21, [CSA]
   Google Scholar
• Lévi F., Zidani R., Llory J. F., Dogliotti L., Perpoint B., Iacobelli S., Chollet P., Focan C., Garufi C., Le Rol A., Giacchetti S., Misset J. L. (2000a) For the International Organization for Cancer Chronotherapy Final Efficacy Update at 7 Years of flat vs Chronomodulated Infusion (Chrono) of Oxaliplatin, 5-Fluorouracil and Leucovorin as First Line Treatment of Metastatic Colorectal Cancer. Proc. 36th Ann. Meeting Am. Soc. Clin. Oncol., New-OrleansU.S.A., May 20–23, 2000. Vol. 19: 242a, (abstr. # 936)
   Google Scholar
• Lévi F., Zidani R., Vannetzel J. M., Perpoint B., Focan C., Faggiuolo R., Chollet P., Garufi C., Itzhaki M., Dogliotti L., Iacobelli S., Adam R., Kunstlinger F., Gastiaburu J., Bismuth H., Jasmin C., Misset J. L. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J. Natl. Cancer Inst. 1994; 86: 1608–1617
   PubMed Web of Science ®Google Scholar
• Li X. M., Liu X. H., Filipski E., Metzger G., Delagrange P., Jeanniot J. P., Lévi F. Relationship of atypical melatonin rhythm with two circadian clock outputs in B6D2F1 mice. Am. J. Physiol.—Regul. Integ. Comp. Physiol. 2000; 278: R924–R930
   PubMed Web of Science ®Google Scholar
• Li X. M., Metzger G., Filipski E., Boughattas N., Lemaigre G., Hecquet B., Filipski J., Lévi F. Pharmacologic modulation of reduced glutathione (GSH) circadian rhythms by buthionine sulfoximine (BSO): relationship with cisplatin (CDDP) toxicity in mice. Toxicol. Appl. Pharmacol. 1997; 143: 281–290, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Marchenay C., Cellarier E., Lévi F., Rolhion C., Kwiatkowski F., Dubray C., Claustrat B., Madelmont J. C., Chollet P. Circadian variation in O6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects. Int. J. Cancer 2001; 91: 60–66, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nelson W., Liang Tong Y., Lee J. K., Halberg F. Methods for cosinor-rhythmometry. Chronobiologia 1979; 6: 305–323
   PubMedGoogle Scholar
• Ohdo S., Makinosumi T., Ishizaki T., Yukawa E., Higuchi S., Nakano S., Ogawa N. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J. Pharmacol. Exp. Ther 1997; 283: 1383–1388, [CSA]
   PubMed Web of Science ®Google Scholar
• Ohno R., Okada K., Masaoka T., Kuramoto A., Arima T., Yoshida Y., Ariyoshi H., Ishimaru M., Sakai Y., Oguro M., Ito Y., Morishima Y., Yokomaku S., Ota K. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 1990; 8: 1907–1912
   PubMed Web of Science ®Google Scholar
• Okamura H., Miyake S., Sumi Y., Yamaguchi S., Yasui A., Muijtjens M., Hoeijmakers J. H., Horst G. T. Photic induction of mPer1 and mPer2 in cry-deficient mice lacking a biological clock. Science 1999; 286: 2531–2534, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J., Awad L., Herait P., Jacques C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407–1412, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., Moore M. J., Maroun J. A., Ackland S. P., Locker P. K., Pirotta N., Elfring G. L., Miller L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl. J. Med. 2000; 343: 905–914, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Schibler U., Sassone-Corsi P. A web of circadian pacemakers. Cell 2002; 111: 919–922, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shearman L. P., Sathyanarayanan S., Weaver D. R., Maywood E. S., Chaves I., Zheng B., Kume K., Lee C., van den Horst G. T. J., Hastings M. H., Reppert S. M. Interacting molecular loops in the mammalian circadian clock. Science 2000; 288: 1013–1018, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sorbye H., Dahl O., Smaaland R. (1997) The Effect of Morning or Late Evening Administration of Irinotecan (CPT–11 ) on Hematological Toxicity. Proc. Int. Cong. on Chronobiology, ParisFrance, Septembre 7–11, 1997, Chronobiol. Int. 1997, 14 (suppl. 1)
   Google Scholar
• Suzuki A., Kato M. Chemotherapeutic agent CPT-11 induces the new expression of the apoptosis initiator to the cytoplasm. Exp. Cell Res. 1996; 227: 154–159, [CROSSREF]
   PubMedGoogle Scholar
• Tampellini M., Filipski E., Liu X. H., Lemaigre G., Li X. M., Vrignaud P., François E., Bissery M.-C., Lévi F. Docetaxel chronopharmacology in mice. Cancer Res. 1998; 58: 3896–904
   PubMed Web of Science ®Google Scholar
• Touitou Y., Portaluppi F., Smolensky M. H., Rensing L. Ethical principles and standards for the conduct of human and animal biological rhythm research. Chronobiol. Int. 2004; 21(1)161–170, [CROSSREF]
   PubMed Web of Science ®Google Scholar